REGENXBIO Declares Shows on the Society for the Research of Inborn Errors of Metabolism Annual Symposium


Rockville, Mohd., August 23, 2022 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX) right now introduced shows on the Society for the Research of Inborn Errors of Metabolism Annual Symposium, happening right here. August 30 to September 2, 2022in Freiburg, Germany, Shows will spotlight new information from the Section I/II/III CAMPSITE™ trial of RGX-121, a one-time AAV scientific trial for the remedy of mucopolysaccharideosis kind II (MPS II), also referred to as Hunter syndrome , and information presentation for an encore RGX-111, an investigative one-time AAV therapeutic for the remedy of extreme mucopolysaccharideosis kind I (MPS I), or Hurler syndrome.

Shows embody:

title: RGX-121 gene remedy for the remedy of extreme mucopolysaccharideosis kind II (MPS II): interim evaluation of information from a part 1/2 research
Presenter: Roberto Giugliani, MD, PhD, Professor, Division of Genetics, UFRGS, Medical Genetics Service, HCPA, porto alegre, brazil
Date Time: Wednesday, August 31, 202210:00 – 10:15 am CEDT

title: RGX-111 gene remedy for the remedy of extreme mucopolysaccharideosis kind I (MPS I): interim evaluation of information from earlier in human research
Presenter: raymond wangMD, Division of Metabolic Issues, CHOC Youngsters’s Hospital, Division of Pediatrics, College of California, IrvineCA
Date Time: Thursday, September 1, 2022, 11:30 – 11:45 am CEDT

title: The pure historical past of neurodevelopment in neuronopathic mucopolysaccharideosis kind II (MPS II): the Mullen scale of early studying (MSEL) cognitive, motor, and language developmental trajectories.
Presenter: Maria Escolar, MD, MS, professor of pediatrics, director, Program for the Research of Neurodevelopment in Uncommon Issues, UPMC Youngsters’s Hospital of pittsburgh
Date Time: Wednesday, August 31, 2022, 6:45 – 8:15 pm CEDT

About REGENXBIO Inc.

REGENXBIO is a number one clinical-stage biotechnology firm looking for to enhance lives via the therapeutic potential of gene remedy. REGENXBIO’s NAV Expertise Platform, a proprietary adeno-associated virus (AAV) gene supply platform, holds unique rights to over 100 novel AAV vectors, together with AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Expertise Platform licensees are implementing the NAV Expertise Platform within the growth of a broad pipeline of candidates, together with late-stage and industrial applications in a number of therapeutic areas. REGENXBIO is dedicated to a “5x’25” technique to progress 5 AAV therapeutics from our inner pipeline and licensed applications into pivotal part or industrial merchandise by 2025.

Contact:

Dana Cormack
industrial communication
[email protected]

Buyers:
Chris Brinze
ICR Westwick
339-970-2843
[email protected]

SOURCE REGENXBIO INC.



Supply hyperlink